HDAC6 and Peritoneal Fibrosis: Our studies suggest that TA, a special inhibitor of HDAC6, can alleviate the development and progression of peritoneal fibrosis, which provides a rationale for using HDAC6-specific inhibitors as potential anti-fibrotic drugs in clinical trials.